Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Sees Unusually High Options Volume (AVDL)

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) saw unusually large options trading activity on Tuesday. Stock traders purchased 562 call options on the company. This is an increase of 981% compared to the average daily volume of 52 call options.

AVDL has been the subject of a number of analyst reports. Ladenburg Thalmann Financial Services raised their target price on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a research note on Thursday, September 7th. Langenberg & Company reaffirmed a “buy” rating and set a $30.00 target price (up previously from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a research note on Thursday, September 7th. Zacks Investment Research downgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BidaskClub raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Roth Capital set a $14.00 price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) opened at $8.84 on Friday. The firm has a market cap of $363.56, a P/E ratio of 4.58 and a beta of 1.34. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 1 year low of $7.52 and a 1 year high of $12.30.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.13. The company had revenue of $39.68 million during the quarter, compared to the consensus estimate of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) earnings per share. research analysts forecast that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.35 EPS for the current fiscal year.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton bought 140,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $8.67 per share, with a total value of $1,213,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael S. Anderson bought 5,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average cost of $8.86 per share, with a total value of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of AVDL. Janus Henderson Group PLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter worth approximately $24,100,000. Stonepine Capital Management LLC boosted its holdings in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 31.7% in the third quarter. Stonepine Capital Management LLC now owns 985,210 shares of the company’s stock worth $10,345,000 after purchasing an additional 237,347 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter worth approximately $2,100,000. Boston Partners purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter worth approximately $1,868,000. Finally, OxFORD Asset Management LLP boosted its holdings in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 62.7% in the second quarter. OxFORD Asset Management LLP now owns 334,881 shares of the company’s stock worth $3,694,000 after purchasing an additional 129,044 shares during the last quarter. Institutional investors own 67.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3126339/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-sees-unusually-high-options-volume-avdl.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.